Icosavax stock soared 47% in Tuesday premarket trading after the Seattle-based vaccine developer reached a deal to be acquired by pharmaceutical giant AstraZeneca.
Continue reading this article with a Barron’s subscription.
Related
Icosavax stock soared 47% in Tuesday premarket trading after the Seattle-based vaccine developer reached a deal to be acquired by pharmaceutical giant AstraZeneca.
Continue reading this article with a Barron’s subscription.
